7 terminated. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma MT-3724, Gemcitabine, Oxaliplatin - Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Molecular Templates, Inc. | 8 | 2018-08-20 | 2022-08-16 |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy Atezolizumab, Rituximab, Gemcitabine 1000 mg - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University Hospital Southampton NHS Foundation Trust | 53 | 2018-05-09 | 2022-08-22 |
| Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Laboratory Biomarker Analysis, Pembrolizumab, Rituximab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 2 | Terminated | University of Washington | 18 | 2018-03-23 | 2025-07-22 |
| Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL Onalespib - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2016-04-04 | 2022-09-13 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Burkitt Lymphoma (1) · Disease Progression (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell (5) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1)
Rituximab (3) · CT-P10 (2) · Gemcitabine (2) · Oxaliplatin (2) · fludarabine (2) · fludarabine phosphate (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cyclosporins (1) · Indium (1) · Interleukin 1 Receptor Antagonist Protein (1) · Mycophenolic Acid (1) · Receptors, Interleukin-6 (1) · Whole-Body Irradiation (1)
University of Washington (2) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Molecular Templates, Inc. (1) · National Cancer Institute (NCI) (1) · University Hospital Southampton NHS Foundation Trust (1)
United States (6) · United Kingdom (1)
Stephen D. Smith (2) · Ajay Gopal (1) · Andy Davies (1) · Caron A Jacobson (1) · John M Timmerman, MD (1)
2016 (1), P01CA044991 (1), P30CA015704 (1), UM1CA186690 (1), UM1CA186709 (1)